Premium
Acute lymphoblastic leukemia in infancy
Author(s) -
Silverman Lewis B.
Publication year - 2007
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.21352
Subject(s) - medicine , cytarabine , blood cancer , lymphoblastic leukemia , disease , adverse effect , clinical trial , oncology , pediatrics , leukemia , cancer , intensive care medicine
Infant ALL is uncommon, biologically distinctive from the disease in older children, and associated with a relatively poor prognosis. Adverse prognostic factors include the presence of an MLL gene rearrangement (observed in up to 80% of infants with ALL), younger age at diagnosis, high presenting leukocyte counts, and slow early response to therapy. The role of stem cell transplant in first remission remains controversial. Current research efforts to improve the outcome of MLL‐rearranged ALL in infants include clinical trials testing cytarabine‐intensive regimens and translational investigations of novel, targeted therapies, such as FLT3‐inhibitors. Pediatr Blood Cancer 2007;49:1070–1073. © 2007 Wiley‐Liss, Inc.